Previous Statements by FOLD
» Amicus Therapeutics CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Amicus Therapeutics Agreement with GSK - Call Transcript
» Amicus Therapeutics, Inc. Q2 2010 Earnings Call Transcript
Futures remain soft, but analysts believe rally still has steam.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.